ADCYAP1 and myeloid sarcoma: Furthermore, we recently published a review article where we discussed the beneficial effects of these peptides in ameliorating several of the neurological comorbidities of MS, outlining the potential usefulness of PACAP/VIP-based therapies as an all-in-one approach to counteract the disease by tackling distinct pathological domains [148].